Fact CheckerSign in

NCT06305481Completed

Glaucoma Evaluation With the P200TE

Source: ClinicalTrials.gov · Last updated 13 Feb 2026

Brief summary (registry, in English)

Images captured on the P200TE device on glaucoma patients

Status (registry)
Completed
Study type
Interventional
Enrollment
53 (actual)
First submitted
5 Mar 2024
Start date
13 Feb 2024
Primary completion date
23 Oct 2024
Lead sponsor
Optos, PLC
Diseases
Glaucoma
NCT number
NCT06305481

What you commit to

  • Study type: Interventional
  • Participants enrolled: 53
  • From 13 Feb 2024 to the primary completion date, 23 Oct 2024
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Subject has a condition or is in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;

Other

  • Subjects unable to tolerate ophthalmic imaging;
  • Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in the study eye;
  • No reliable visual field test result within the past year of the study visit, defined as fixation losses \> 33% or false positives \>33%, or false negatives \>33% in the study eye;
  • Presence of any ocular pathology except glaucoma in the study eye.

Who the study is looking for

  • Subjects were 22 years of age or older on the date of informed consent;
  • Subjects were able to understand the written informed consent and willing to participate as evidenced by signing the informed consent;
  • BCVA 20/40 or better in the study eye;
  • History of visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:
    • On pattern deviation (PD), there existed a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; or Glaucoma hemi-field test "outside normal limits;"
    • -Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities: Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage; and Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.

Age in the registry: 22 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Specialty Eyecare Centre
Coordinator of this site? Confirm its status
BellevueUnited StatesUnknown status
Werner Optometry
Coordinator of this site? Confirm its status
CajonUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.